These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 28875845)

  • 1. New Trends in Anti-Cancer Therapy: Combining Conventional Chemotherapeutics with Novel Immunomodulators.
    Wilson AL; Plebanski M; Stephens AN
    Curr Med Chem; 2018; 25(36):4758-4784. PubMed ID: 28875845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Systematic Review of Immunotherapy in Urologic Cancer: Evolving Roles for Targeting of CTLA-4, PD-1/PD-L1, and HLA-G.
    Carosella ED; Ploussard G; LeMaoult J; Desgrandchamps F
    Eur Urol; 2015 Aug; 68(2):267-79. PubMed ID: 25824720
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
    Philips GK; Atkins M
    Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rationale for anti-OX40 cancer immunotherapy.
    Aspeslagh S; Postel-Vinay S; Rusakiewicz S; Soria JC; Zitvogel L; Marabelle A
    Eur J Cancer; 2016 Jan; 52():50-66. PubMed ID: 26645943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunotherapy in cancer. Current prospects, challenges and new horizons].
    Dalotto-Moreno T; Blidner AG; Girotti MR; Maller SM; Rabinovich GA
    Medicina (B Aires); 2018; 78(5):336-348. PubMed ID: 30285926
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1/PD-L1 and immunotherapy for pancreatic cancer.
    Feng M; Xiong G; Cao Z; Yang G; Zheng S; Song X; You L; Zheng L; Zhang T; Zhao Y
    Cancer Lett; 2017 Oct; 407():57-65. PubMed ID: 28826722
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.
    McArthur HL; Page DB
    Clin Adv Hematol Oncol; 2016 Nov; 14(11):922-933. PubMed ID: 27930644
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New frontiers in oncology: Immune checkpoint inhibitors in combination therapy.
    Romano G; Gawlinski A
    Drugs Today (Barc); 2017 Feb; 53(2):103-115. PubMed ID: 28387388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Checkpoint blocking antibodies in cancer immunotherapy.
    Kyi C; Postow MA
    FEBS Lett; 2014 Jan; 588(2):368-76. PubMed ID: 24161671
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunomodulating and Immunoresistance Properties of Cancer-Initiating Cells: Implications for the Clinical Success of Immunotherapy.
    Maccalli C; Parmiani G; Ferrone S
    Immunol Invest; 2017 Apr; 46(3):221-238. PubMed ID: 28287848
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Importance of immune monitoring approaches and the use of immune checkpoints for the treatment of diffuse intrinsic pontine glioma: From bench to clinic and vice versa (Review).
    Scutti JAB
    Int J Oncol; 2018 Apr; 52(4):1041-1056. PubMed ID: 29484440
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Novel approaches in cancer immunotherapy -- a light at the end of the tunnel.
    Joshi M; Pal SK; Drabick JJ
    Discov Med; 2016 Jun; 21(118):479-87. PubMed ID: 27448784
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment.
    Gorris MAJ; Halilovic A; Rabold K; van Duffelen A; Wickramasinghe IN; Verweij D; Wortel IMN; Textor JC; de Vries IJM; Figdor CG
    J Immunol; 2018 Jan; 200(1):347-354. PubMed ID: 29141863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Breaking immune tolerance in cancer].
    Desbois M; Champiat S; Chaput N
    Bull Cancer; 2015 Jan; 102(1):34-52. PubMed ID: 25609492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immuno-regulatory antibodies for the treatment of cancer.
    Honeychurch J; Cheadle EJ; Dovedi SJ; Illidge TM
    Expert Opin Biol Ther; 2015 Jun; 15(6):787-801. PubMed ID: 25882106
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint modulation for non-small cell lung cancer.
    Soria JC; Marabelle A; Brahmer JR; Gettinger S
    Clin Cancer Res; 2015 May; 21(10):2256-62. PubMed ID: 25979932
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging role of immunotherapy in urothelial carcinoma-Immunobiology/biomarkers.
    Sweis RF; Galsky MD
    Urol Oncol; 2016 Dec; 34(12):556-565. PubMed ID: 27836246
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune Checkpoint Inhibitors in Lung Cancer - An Unheralded Opportunity?
    Marshall R; Popple A; Kordbacheh T; Honeychurch J; Faivre-Finn C; Illidge T
    Clin Oncol (R Coll Radiol); 2017 Apr; 29(4):207-217. PubMed ID: 28063623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy.
    Lu J; Lee-Gabel L; Nadeau MC; Ferencz TM; Soefje SA
    J Oncol Pharm Pract; 2015 Dec; 21(6):451-67. PubMed ID: 24917416
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intratumoral immunotherapy: using the tumor as the remedy.
    Marabelle A; Tselikas L; de Baere T; Houot R
    Ann Oncol; 2017 Dec; 28(suppl_12):xii33-xii43. PubMed ID: 29253115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.